© Getty Images

Dupixent -

Dupixent (dupilumab) is an interleukin-4 receptor alpha antagonist used for the treatment of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis, and chronic obstructive pulmonary disease (COPD).

© Getty Images

Amtagvi -

Amtagvi (lifileucel) is the first cellular therapy for treating adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies.

© Shutterstock

Xolair -

Xolair is the first FDA-approved medication to reduce allergic reactions to more than one type of food after accidental exposure. Xolair was originally approved in 2003 for the treatment of moderate to severe persistent allergic asthma in certain patients. Xolair is also approved to treat chronic spontaneous urticaria and chronic rhinosinusitis with nasal polyps in certain patients.

© Shutterstock

Wegovy -

Wegovy is the first FDA-approved weight-management medicine that lowers the risk of major cardiovascular events in adults with obesity and known heart disease.

© Getty Images

Tryvio -

Tryvio (generic name: aprocitentan) is a once-daily medication, a dual oral endothelin receptor antagonist (ERA), used to treat high blood pressure that is not adequately controlled by other antihypertensive medications.

© Shutterstock

Nexletol -

Nexletol (generic name: bempedoic acid) is an oral medication used to lower LDL (bad) cholesterol levels in adults with high cholesterol. It is particularly beneficial for those who cannot tolerate statins or need additional cholesterol-lowering treatment.

© Shutterstock

Winrevair -

Winrevair is a medicine used to improve the ability to exercise in adults with pulmonary arterial hypertension (PAH).

© Getty Images

mResvia -

mResvia is a vaccine for protecting against lower respiratory tract disease (diseases of the lungs such as bronchitis or pneumonia) caused by respiratory syncytial virus (RSV) in adults aged 60 years and older. 

© Shutterstock

Capvaxive -

Capvaxive is a vaccine for individuals 18 years of age and older to help protect against invasive pneumococcal disease and pneumonia caused by certain types of bacteria called pneumococcus.

© Shutterstock

Wakix -

Wakix is a prescription medicine used to treat excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. It is also approved for treating excessive daytime sleepiness (EDS) in children six years of age and older with narcolepsy.

© Shutterstock

Ohtuvayre -

Ohtuvayre is an inhaled, steroid-free suspension that may be used as maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults. It can improve symptoms and reduce the number of flare-ups.

© Shutterstock

Kisunla -

Kisunla is for adults with early symptomatic Alzheimer's disease, which includes the mild cognitive impairment or mild dementia stage of the disease.

© Getty Images

Zunveyl -

Zunveyl is approved by the US Food and Drug Administration (FDA) as a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults.

© Shutterstock

Yorvipath -

Yorvipath is a hormone replacement medicine for treating adults with chronic hypoparathyroidism.

© Shutterstock

Neffy -

Neffy is the first and only needle-free epinephrine nasal spray for adults and children weighing 66 lbs or more. It claims to be the only medication proven to stop a potentially life-threatening allergic reaction.

© Getty Images

FluMist -

FluMist is a vaccine in the form of a nasal spray approved for the prevention of influenza disease caused by influenza virus subtypes A and B in individuals two through 49 years of age. In 2024, the FDA approved it for self- or caregiver-administration.

© Getty Images

Cobenfy - Cobenfy is an oral prescription medicine used to treat adults with schizophrenia.

© Shutterstock

Yesintek -

Yesintek (ustekinumab-kfce) is a human interleukin-12 and -23 antagonist biosimilar to Stelara used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

© Shutterstock

Aucatzyl -

Aucatzyl is used for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

© Shutterstock

Kebilidi -

Kebilidi (eladocagene exuparvovec-tneq) is a gene replacement therapy for use in the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency.

© Shutterstock

Revuforj -

Revuforj is a first-in-class menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients of one year and older.

© Shutterstock

Ziihera - Ziihera (zanidatamab-hrii) is a bispecific HER2-directed antibody for the treatment of HER2-positive biliary tract cancer.

© Shutterstock

Attruby -

Attruby (acoramidis) is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

© Shutterstock

Opdivo Qvantig - Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) is a programmed death receptor-1 (PD-1)-blocking antibody and hyaluronidase combination for use in the treatment of renal cell carcinoma, melanoma, non-small cell lung cancer, squamous cell carcinoma of the head and neck, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal cancer, gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

© Shutterstock

Alhemo -

Alhemo (concizumab-mtci) is a tissue factor pathway inhibitor (TFPI) antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B with inhibitors.

© Shutterstock

Steqeyma -

Steqeyma (ustekinumab-stba) is a human interleukin-12 and -23 antagonist biosimilar to Stelara used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

© Shutterstock

Alyftrek -

Alyftrek (deutivacaftor, tezacaftor and vanzacaftor) is a next-in-class, triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for use in the treatment of cystic fibrosis.

© Shutterstock

Unloxcyt -

Unloxcyt (cosibelimab-ipdl) is a programmed death ligand-1 (PD-L1) blocking antibody used for the treatment of cutaneous squamous cell carcinoma.

Sources: (FDA) (Fox News) (Drugs.com) (Fierce Pharma)

See also: How do medicines get their names?

© Getty Images